Unlike many other cancers, most pancreatic tumors are rock hard.
“That’s one reason why pancreatic cancer is one of the most lethal types of cancer,” says Kenneth Olive, PhD, associate professor of medicine and pathology & cell biology at Columbia University Vagelos College of Physicians and Surgeons and a pancreatic cancer researcher at the Herbert Irving Comprehensive Cancer Center.
“Pancreatic tumors recruit a thick layer of connective tissue called stroma that hardens the tumor and acts like a shield,” says Olive, whose previous research first uncovered how the stroma makes it difficult for chemotherapy drugs to reach malignant cells. “As a result, most chemotherapy drugs can’t build up to the levels needed to be effective.”
To Olive, that suggests, paradoxically, a longer-lived—but less toxic—drug may work better.
“For a pancreatic cancer drug to be effective, it needs to stick around long enough to seep past the stroma and accumulate in the tumor. But if it is going to persist for a long time in the blood, it can’t be as toxic to the rest of the body,” he says.
Pancreatic Ductal Adenocarcinoma
Despite some recent improvements in pancreatic cancer treatment, the five-year survival rate for individuals with this disease is only around 9%.
Testing a New Drug Combination
Olive’s latest research, which was led by Jaime Eberle-Singh, PhD, while she was a graduate student at Columbia, may have identified a good candidate. The drug, an experimental compound called PTC596 that had shown antitumor activity in mouse and human pancreatic cancer cells, seemed to have the right qualities: PTC596 has a durable half-life (most cancer drugs have a half-life of a few minutes to hours) and can evade a pump that many cancer cells use to expel drugs. “This means that any amount of drug that makes it past the barrier can target the malignant cells,” says Olive.
Based on those studies, Olive, Eberle-Singh, and their collaborators tested PTC596 in combination with gemcitabine (a first-line drug for pancreatic cancer) in genetically engineered mice with an aggressive form of pancreatic cancer that is generally resistant to chemotherapy.
The mice that were treated with the two-drug combination lived three times longer than those treated with only a single standard agent. “This result was exciting because it’s exceedingly rare for any treatment to extend survival in this gold-standard mouse model,” Olive says.
They also tested PTC596 in combination with gemcitabine and another drug commonly used to treat pancreatic cancer, nab-paclitaxel, using human pancreatic tumors grown in mice. This combination further enhanced efficacy, making the tumors shrink outright.
“Based on the drug’s safety profile and our own findings, there’s a good rationale for testing PTC596 in combination with standard therapy in patients with pancreatic cancer,” says Olive.
Olive’s team also discovered that PTC596 blocks the formation of microtubules—a network of proteins involved in cell division and transport of nutrients within the cell. He demonstrated that PTC596 may act synergistically with nab-paclitaxel, another microtubule-binding agent.
“Combining different microtubule inhibitors has the potential to play an important role in the future of oncology, as there are many agents that each impact microtubules in different ways that could produce synergy,” Olive says.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Adavosertib regimen appears safe, shows promise for improving pancreatic cancer survivalon August 22, 2019 at 11:46 am
The combination of adavosertib, gemcitabine and radiation appeared safe and potentially effective for patients with newly diagnosed, locally advanced pancreatic cancer, according to results of a phase ...
- Revealing the molecular engine that drives pancreatic cancer provides ways to turn it offon August 22, 2019 at 8:03 am
Researchers at Georgetown Lombardi Comprehensive Cancer Center have decoded a chain of molecules that are critical for the growth and survival of pancreatic ductal adenocarcinoma (PDAC)—the most ...
- New cannabis-based drug shows promise for pancreatic canceron August 21, 2019 at 11:41 pm
Cancer of the pancreas is a particularly deadly cancer, claiming over 90% of its victims within 5 years from diagnosis. It resists most standard therapies, including surgery, chemotherapy, radiation ...
- NuCana Stops Patient Enrollment in Pancreatic Cancer Studyon August 21, 2019 at 5:18 pm
NuCana plc NCNA announced that it has suspended enrollment of patients in the ongoing phase III ACELARATE study on its most advanced pipeline candidate Acelarin. The study was evaluating the ...
- Study: Cannabis Chemical May Have ‘Major Impact’ On Pancreatic Cancer Treatmenton August 21, 2019 at 11:55 am
(CBS Local) — A chemical found in the cannabis plant has demonstrated “significant therapy potential” in treatment of pancreatic cancer, according to researchers from Harvard University’s ...
- Scientific Study: This Marijuana Flavor Might Fight Pancreatic Canceron August 21, 2019 at 9:13 am
Often lost in the dishonest hubbub around wellness-trend-of-the-moment CBD—and all the afflictions that the non-intoxicating cannabis compound can supposedly heal—are the legitimate scientific ...
- NuCana's Acelarin fails to beat chemo in pancreatic cancer study; shares down 20% premarketon August 20, 2019 at 10:56 am
Thinly traded micro cap NuCana plc (NASDAQ:NCNA) slumps 20% premarket on light volume in reaction to its decision to suspend enrollment in the Phase 3 ACELARATE study evaluating Acelarin as ...
- Study on cannabis chemical as a treatment for pancreatic cancer may have 'major impact,' Harvard researcher sayson August 20, 2019 at 9:59 am
Pancreatic cancer makes up just 3 percent of all cancers in America. But with a one-year survival rate of just 20 percent (and five-year survival rate of less than 8), it’s predicted to be the second ...
- NuCana stock falls 21% after company suspends patient enrollment in pancreatic cancer trialon August 20, 2019 at 8:00 am
Shares of NuCana Plc NCNA, -2.32% fell 21% on Tuesday after the company announced it had suspended the enrollment of new patients in a late-stage trial of a pancreatic cancer drug. Researchers were ...
- Pancreatic Cancer Treatment Successfully Targets Cell Cycleon August 20, 2019 at 5:24 am
Testing and repurposing various anticancer drugs on tumors they were not specifically designed for has often led to unexpected and positive results. So goes the story with a new study from ...
via Bing News